C4 Therapeutics announces 2023 priorities, Phase 1 data expected in 2H 2023 for CFT7455 and CFT8634

C4 Therapeutics, Inc.

Cash, cash equivalents and marketable securities of $366M as of Sep 30, 2022; expected to fund operations to end of 2024.
Phase 1/2 trial of CFT7455 (IKZF1/3 degrader for multiple myeloma) continues; Phase 1 dose escalation data expected in 2H 2023.
Phase 1/2 trial of CFT8634 (BRD9 degrader for synovial sarcoma) continues; Phase 1 data expected in 2H 2023; PK/PD data supportive of proof of mechanism.
Phase 1/2 trial of CFT1946 (BRAF-V600 degrader for solid tumors) initiated; IND submission for CFT8919 (EGFR L858R NSCLC) planned in 1H 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.